The signature also prognosticated in three independent cohorts of ER+ breast cancer patients: the NKI cohort using custom spotted cDNA arrays [58], and the TCGA cohort [78] and BT2000/Metabric cohorts [79] both using Illumina arrays (Additional file 12). This evidence concerns the gene ESR1 and breast cancer.